In adults who are overweight or obese but do not have diabetes, tirzepatide lowers both body mass index and blood sugar levels compared to other similar medications.
Mechanism
Synthesis from 1 study
This drug works better than others because it turns on two different signals in the body at once: one that makes you feel full and eat less, and another that helps your body use sugar more efficiently. Losing weight from eating less then helps your liver stop making too much sugar, which lowers...
Most probable mechanism
A drug that activates two specific receptors in the body — one that tells the brain to feel full and another that helps fat and muscle use sugar better — causes a person to eat less, lose weight, and lower their blood sugar. The weight loss improves how the liver handles sugar, and the combined effect on insulin makes the body more efficient at clearing sugar from the blood without needing extra insulin production.
Activation of GLP-1 receptors in the hypothalamus and brainstem increases feelings of fullness and reduces appetite, leading to decreased caloric intake
Activation of GIP receptors on adipose tissue enhances insulin sensitivity, promoting glucose uptake into fat and muscle cells and reducing circulating glucose levels
Co-activation of GIP and GLP-1 receptors on pancreatic beta cells increases glucose-dependent insulin secretion while suppressing glucagon release, improving overall glycemic control
Reduction in body weight decreases hepatic fat accumulation and suppresses excessive glucose production by the liver
Improved insulin sensitivity and reduced hepatic glucose output synergistically lower fasting and postprandial blood glucose levels
Less supported by current evidence, but not ruled out
Activation of GLP-1 receptors on immune cells reduces the release of inflammatory signals, which lowers liver production of a marker linked to metabolic stress and improves how the body clears fat from the blood.
GLP-1 receptor activation on monocytes and macrophages suppresses NF-kB signaling and reduces secretion of pro-inflammatory cytokines
Reduced cytokine levels decrease hepatic synthesis of C-reactive protein and other acute-phase reactants
GLP-1 receptor activation enhances clearance of low-density lipoprotein and reduces very-low-density lipoprotein secretion by the liver
Activation of GLP-1 receptors in the kidneys causes more salt and water to be excreted in urine, while also reducing a hormone that narrows blood vessels, leading to lower blood pressure.
GLP-1 receptor activation in renal tubules increases sodium and water excretion
GLP-1 receptor activation inhibits renin release, reducing angiotensin II production and causing blood vessels to relax
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.